Imugene Ltd has released a press release.
Imugene doses first combination patient in PD1-Vaxx trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Imugene secures IND approval for first-in-class onCARlytics trial
- FDA clears Imugene IND for onCARlytics first-in-class study
- onCARlytics with ARTEMIS T cells show anti-tumour activity
- onCARlytics with Artemis T cells abstract presented at ASGCT
- Imugene receives $12.6m R&D tax refund
Later from Imugene
- Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
- Imugene PD1-Vaxx patent extended to 2040
- HER-Vaxx induced antibodies correlated with tumour reduction
- New Dose Escalation in Phase I Clinical Trial of CHECKvacc
- Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene